Why Full FDA Approval of Pfizer Vaccine Was Not the “Quick Fix” to Immunization Rates

[ad_1]

Pop-up vaccine clinic sign. Justin Sullivan / Getty Images

Even though health officials hoped the opposite was true, federal government analysis suggests full FDA approval of Pfizer’s COVID-19 vaccine had only a “modest and relatively short-lived effect.” On vaccination rates, reports CNN. In other words, while there was A slight increase that resulted, a full license was not the “silver bullet” to completely eliminate vaccine reluctance.

“There weren’t suddenly any queues around the block,” said Becca Siegel, senior advisor for the US Department of Health and Human Services. That’s because for “people who are really indecisive, it’s a complex decision. It’s not a thing,” Siegel explained.

Notably, fear (whether of getting sick or missing), social pressure from friends and families, employer mandates, and concerns about the Delta variant were more likely to boost immunization rates among children. individuals hesitant about full FDA approval, CNN notes, Kaiser Family Foundation poll.

Still, licensure could play a long-term role in convincing Americans to roll up their sleeves. “We won’t see the impact of the approval on the first day, the first hour, but we could see it over a long period of time,” Siegel said. “It’s a slow, steady walk.”

And as the United States gets closer to the finish line, “I think we’ve come to recognize that warrants are what we’ve come to in order to really generate an increase in immunization,” added John. Browstein of Boston Children’s Hospital. “The warrants are super important to cover the last mile for those on the fence.” Learn more on CNN.

You may also like